Befizal

Befizal is a prescription medication that contains the active ingredient bezafibrate, a fibrate class lipid‑lowering agent, supplied in an oral dosage form (strength not specified). It is marketed in the European Union and is classified under ATC code C10AB01. Bezafibrate works by activating peroxisome proliferator‑activated receptor‑alpha (PPARα) to enhance the breakdown and clearance of triglyceride‑rich lipoproteins, helping to manage abnormal blood lipid levels in patients.

Befizal is indicated for the treatment of several lipid disorders where reduction of triglycerides and improvement of cholesterol profiles are desired.

- Patients with primary or secondary hyperlipidemia, especially those with markedly elevated triglyceride concentrations. - Individuals diagnosed with hypertriglyceridemia, including cases where triglyceride levels exceed 200 mg/dL and pose a risk for pancreatitis. - People with mixed dyslipidemia characterized by high low‑density lipoprotein (LDL) cholesterol together with elevated triglycerides. - Patients who have not achieved target lipid levels through dietary modification, exercise, or other non‑pharmacologic measures alone. - Use as part of a comprehensive cardiovascular risk‑reduction strategy in conjunction with statins or other lipid‑lowering agents, when clinically appropriate.

The safety profile of Befizal reflects the typical adverse events observed with fibrate therapy; most are mild and reversible, while rare serious reactions may occur.

Common: - Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia. - Muscle aches or mild myalgia without significant weakness. - Elevated liver enzymes (transaminases) that are usually transient. - Headache or dizziness.

Serious: - Myopathy or rhabdomyolysis, particularly when combined with statins. - Severe liver injury presenting as jaundice or marked enzyme elevation. - Acute renal failure or worsening of pre‑existing kidney disease. - Allergic reactions including rash, pruritus, or angioedema.

Before initiating Befizal, clinicians should evaluate several clinical factors to minimize risk and ensure appropriate use.

- Assess baseline liver function tests; avoid use in patients with active hepatic disease. - Review renal function; dose adjustment may be needed in moderate to severe impairment. - Screen for a history of gallstones, as fibrates can increase biliary cholesterol saturation. - Evaluate for concurrent use of statins or other myotoxic drugs, monitoring for muscle toxicity. - Consider pregnancy and lactation status; safety data are limited, and use is generally avoided. - Monitor lipid panels and liver enzymes periodically during therapy. - Counsel patients on adhering to a low‑fat diet and avoiding excessive alcohol.

Befizal can affect the metabolism of other medicines; certain combinations should be avoided, while others require careful monitoring.

Avoid: - Concurrent use with strong CYP2C8 inhibitors (e.g., gemfibrozil) due to increased risk of myopathy. - Co‑administration with high‑dose statins (especially simvastatin) that raises the likelihood of rhabdomyolysis. - Combination with anticoagulants such as warfarin without dose adjustment, as fibrates may enhance anticoagulant effect.

Use with caution: - Concurrent therapy with other lipid‑lowering agents (e.g., niacin) may increase hepatic enzyme elevations. - Use alongside nephrotoxic drugs (e.g., NSAIDs, aminoglycosides) in patients with reduced renal function. - Combination with oral hypoglycemic agents may affect blood glucose control; monitor glycemic parameters.